114 related articles for article (PubMed ID: 2917019)
61. Effect of a conjugate of daunomycin and purified polyclonal or monoclonal antibodies to rat alpha-fetoprotein on the growth of alpha-fetoprotein-producing tumor cells.
Tsukada Y; Hurwitz E; Kashi R; Sela M; Hibi N; Hara A; Hirai H
Ann N Y Acad Sci; 1983; 417():262-9. PubMed ID: 6200034
[TBL] [Abstract][Full Text] [Related]
62. Daunorubicin coupled to monoclonal antibodies via a cis-aconitic anhydride linker: biochemical and cytotoxic properties revisited.
Ahmad A; Law KL; Young B; Telander MW; Ogden JR; Leung K
Anticancer Res; 1990; 10(3):837-43. PubMed ID: 2369097
[TBL] [Abstract][Full Text] [Related]
63. Ricin A chain conjugated with monoclonal antibodies selectively killing human carcinoma cells in vitro.
Canevari S; Orlandi R; Ripamonti M; Tagliabue E; Aguanno S; Miotti S; Menard S; Colnaghi MI
J Natl Cancer Inst; 1985 Nov; 75(5):831-9. PubMed ID: 3863986
[TBL] [Abstract][Full Text] [Related]
64. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.
Safavy A; Bonner JA; Waksal HW; Buchsbaum DJ; Gillespie GY; Khazaeli MB; Arani R; Chen DT; Carpenter M; Raisch KP
Bioconjug Chem; 2003; 14(2):302-10. PubMed ID: 12643740
[TBL] [Abstract][Full Text] [Related]
65. Monoclonal antibody identification and characterization of a Mr 43,000 membrane glycoprotein associated with human breast cancer.
Edwards DP; Grzyb KT; Dressler LG; Mansel RE; Zava DT; Sledge GW; McGuire WL
Cancer Res; 1986 Mar; 46(3):1306-17. PubMed ID: 3510721
[TBL] [Abstract][Full Text] [Related]
66. Increase of daunorubicin and vincristine accumulation in multidrug resistant human ovarian carcinoma cells by a monoclonal antibody reacting with P-glycoprotein.
Broxterman HJ; Kuiper CM; Schuurhuis GJ; Tsuruo T; Pinedo HM; Lankelma J
Biochem Pharmacol; 1988 Jun; 37(12):2389-93. PubMed ID: 2898943
[TBL] [Abstract][Full Text] [Related]
67. Role of differential drug uptake, efflux, and binding of etoposide in sensitive and resistant human tumor cell lines: implications for the mechanisms of drug resistance.
Politi PM; Sinha BK
Mol Pharmacol; 1989 Mar; 35(3):271-8. PubMed ID: 2564628
[TBL] [Abstract][Full Text] [Related]
68. Monoclonal antibody conjugated magnetic nanoparticles could target MUC-1-positive cells in vitro but not in vivo.
Shanehsazzadeh S; Gruettner C; Lahooti A; Mahmoudi M; Allen BJ; Ghavami M; Daha FJ; Oghabian MA
Contrast Media Mol Imaging; 2015; 10(3):225-36. PubMed ID: 25327822
[TBL] [Abstract][Full Text] [Related]
69. Effect of variations in peptide sequence on anti-human milk fat globule membrane antibody reactions.
Xing PX; Reynolds K; Pietersz GA; McKenzie IF
Immunology; 1991 Feb; 72(2):304-11. PubMed ID: 1707852
[TBL] [Abstract][Full Text] [Related]
70. Specific binding and internalization of monoclonal antibody HI98-daunorubicin conjugate by human leukemic cells (HL60).
Liu J; Zhu Z; Liu J; Yin S; Chu Y; Qi S; Yang C; Chen Z
Chin Med Sci J; 1991 Sep; 6(3):157-9. PubMed ID: 1793879
[TBL] [Abstract][Full Text] [Related]
71. Chemotherapy by intravenous administration of conjugates of daunomycin with monoclonal and conventional anti-rat alpha-fetoprotein antibodies.
Tsukada Y; Hurwitz E; Kashi R; Sela M; Hibi N; Hara A; Hirai H
Proc Natl Acad Sci U S A; 1982 Dec; 79(24):7896-9. PubMed ID: 6185954
[TBL] [Abstract][Full Text] [Related]
72. Enhanced antitumour effect of liposomal daunorubicin using antibody-phospholipase C conjugates or fusion protein.
Carter G; White P; Fernie M; King S; McLean G; Titball R; Carr FJ
Int J Oncol; 1998 Oct; 13(4):819-25. PubMed ID: 9735413
[TBL] [Abstract][Full Text] [Related]
73. Cytotoxicity of transferrin-daunorubicin conjugates on small cell carcinoma of the lung (SCCL) cell line NCI-H69.
Béjaoui N; Pagé M; Nöel C
Anticancer Res; 1991; 11(6):2211-3. PubMed ID: 1663723
[TBL] [Abstract][Full Text] [Related]
74. The 95-kilodalton membrane glycoprotein overexpressed in novel multidrug-resistant breast cancer cells is NCA, the nonspecific cross-reacting antigen of carcinoembryonic antigen.
Ross DD; Gao Y; Yang W; Leszyk J; Shively J; Doyle LA
Cancer Res; 1997 Dec; 57(24):5460-4. PubMed ID: 9407950
[TBL] [Abstract][Full Text] [Related]
75. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells.
Zhang L; Yao HJ; Yu Y; Zhang Y; Li RJ; Ju RJ; Wang XX; Sun MG; Shi JF; Lu WL
Biomaterials; 2012 Jan; 33(2):565-82. PubMed ID: 21983136
[TBL] [Abstract][Full Text] [Related]
76. Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy.
Gervasoni JE; Fields SZ; Krishna S; Baker MA; Rosado M; Thuraisamy K; Hindenburg AA; Taub RN
Cancer Res; 1991 Sep; 51(18):4955-63. PubMed ID: 1680024
[TBL] [Abstract][Full Text] [Related]
77. In vitro cytotoxicity of the conjugate adriamycin with anti-sarcoma monoclonal antibody 19-24.
Mohamed G; Kuzmanoff KM; Stastny JJ; Das Gupta TK
Anticancer Res; 1992; 12(2):529-32. PubMed ID: 1580569
[TBL] [Abstract][Full Text] [Related]
78. A novel method of conjugation of daunomycin with antibody with a poly-L-glutamic acid derivative as intermediate drug carrier. An anti-alpha-fetoprotein antibody-daunomycin conjugate.
Kato Y; Umemoto N; Kayama Y; Fukushima H; Takeda Y; Hara T; Tsukada Y
J Med Chem; 1984 Dec; 27(12):1602-7. PubMed ID: 6209394
[TBL] [Abstract][Full Text] [Related]
79. An apocrine membrane antigen with polarized distribution and hormonally regulated expression in human endometrial and mammary carcinoma cell lines.
Forsman LM
Acta Pathol Microbiol Immunol Scand A; 1987 Nov; 95(6):315-23. PubMed ID: 3687435
[TBL] [Abstract][Full Text] [Related]
80. Immunoconjugate design: a predictive approach for coupling of daunomycin to monoclonal antibodies.
Hudecz F; Ross H; Price MR; Baldwin RW
Bioconjug Chem; 1990; 1(3):197-204. PubMed ID: 2096913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
